TECH (Bio-Techne) Total Liabilities : $626 Mil (As of Mar. 2025)

View and export this data going back to 1989. Start your Free Trial

What is Bio-Techne Total Liabilities?

Bio-Techne's Total Liabilities for the quarter that ended in Mar. 2025 was $626 Mil.

Bio-Techne's quarterly Total Liabilities declined from Sep. 2024 ($597.37 Mil) to Dec. 2024 ($591.93 Mil) but then increased from Dec. 2024 ($591.93 Mil) to Mar. 2025 ($626.23 Mil).

Bio-Techne's annual Total Liabilities increased from Jun. 2022 ($593.79 Mil) to Jun. 2023 ($672.18 Mil) but then declined from Jun. 2023 ($672.18 Mil) to Jun. 2024 ($635.02 Mil).

Bio-Techne Total Liabilities Historical Data

The historical data trend for Bio-Techne's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Total Liabilities Chart

Bio-Techne Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Liabilities

Get a 7-Day Free Trial

646.40

691.72

593.79

672.18

635.02

Bio-Techne Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															706.80	635.02	597.37	591.93	626.23

Bio-Techne Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bio-Techne's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	159.379	+	(406.618	+	13.157
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	55.863	+	0	+	0)
	=	635

Total Liabilities	=	Total Assets (A: Jun. 2024 )	-	Total Equity (A: Jun. 2024 )
	=	2703.867	-	2068.85
	=	635

Bio-Techne's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	169.204	+	(409.45	+	15.656
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	31.924	+	0	+	0)
	=	626

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	2644.259	-	2018.025
	=	626

Bio-Techne Total Liabilities Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Techne Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (NAS:TECH) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

TE1:Germany TE1:Germany T1CH34:Brazil

Address

614 McKinley Place N.E., Minneapolis, MN, USA, 55413

Website

https://www.bio-techne.com

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Executives

Kim Kelderman	officer: Pres. Diagnostics & Genom	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Robert V Baumgartner	director	5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416
John L Higgins	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Roeland Nusse	director	473 TENNESSEE, PALO ALTO CA 94306
William Geist	officer: PRESIDENT, PROTEIN SCIENCES	900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821
Charles R. Kummeth	director, officer: Chief Executive Officer	425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
Shane Bohnen	officer: SVP - General Counsel	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Brenda S. Furlow	officer: SVP - General Counsel	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Norman David Eansor	officer: SVP Biotech	8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
James Hippel	officer: Chief Financial Officer	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Joseph D Keegan	director	C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089
Julie L Bushman	director	185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214
Rupert Vessey	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Alpna Seth	director	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Randolph C Steer	director	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413